Role of drug regulatory agency of Pakistan, pharmaceutical industries and their compliance

2^nd International Conference and Exhibition on Pharmaceutical Regulatory Affairs

November 23-24, 2012 Hyderabad International Convention Centre, India

Jibran Khan and Abdu Wahab

Accepted Abstracts: Pharmaceut Reg Affairs

Abstract :

Pakistan is a small country as compared to India and China; however it has substantial share in pharmaceutical market of Asia. Pakistan is a strategically very important and big hub for import and export of basic and finished pharmaceutical products, biologicals, herbal and homeopathic medicines, pharmaceutical equipments etc. In Pakistan, there are small as well as large pharmaceutical units and they are following guidelines of European Medicines Agency (EMA), US Food and Drug Administration (US-FDA) and International Conference on Harmonisation (ICH). Industry quality compliance ratio has improved over the years, and we are producing high quality finished pharmaceutical products. There are six hundred ten pharmaceutical units in Pakistan; these units are under the control of Drug regulatory Agency (National Regulation and Services Division). Employee of regulatory bodies are getting training from US-FDA, EMA, and ICH etc. and improving current Good Manufacturing Practice. We have a great potential in herbal medicines and we have explored the world best markets due to high quality. There are different research institutes which are collaborating with industries and helping in conducting basic and clinical studies. The number of local and multinational units in Pakistan has greatly increased in last 10 years, which are offering variety of pharmaceutical products and due to competition the price of finished products are low and affordable for most of the people of Pakistan. However, still much have to be achieved in order to reach the American and European pharmaceutical standard.

Biography :

Jibran Khan has completed his undergraduate studies in Faculty of Pharmacy, Sindh University, Jamshoro, Pakistan in 2004 and postgraduate studies in Department of Pharmacology, Faculty of Pharmacy, University of Karachi, Pakistan in 2007. He has got few years of experience of working in regulatory compliance department of pharmaceutical industries. His research interest includes preclinical studies using in vivo animal seizure models. He is also involved in clinical studies on the effects of new antiepileptic drugs in epileptic patients.